Synopsis
Synopsis
0
CEP/COS
0
EU WC
0
KDMF
0
VMF
0
Australia
0
South Africa
0
Listed Dossiers
0
EDQM
0
USP
0
JP
0
Others
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
Annual Reports
NA
1. 2 Aminoethanethiol
2. 2-aminoethanethiol
3. 35s-labeled Cysteamine
4. Becaptan
5. Beta Mercaptoethylamine
6. Beta-mercaptoethylamine
7. Bitartrate, Cysteamine
8. Cystagon
9. Cysteamine
10. Cysteamine Dihydrochloride
11. Cysteamine Hydrobromide
12. Cysteamine Hydrochloride
13. Cysteamine Maleate (1:1)
14. Cysteamine Tartrate
15. Cysteamine Tartrate (1:1)
16. Cysteamine Tosylate
17. Cysteamine, 35s Labeled
18. Cysteamine, 35s-labeled
19. Cysteinamine
20. Dihydrochloride, Cysteamine
21. Hydrobromide, Cysteamine
22. Hydrochloride, Cysteamine
23. Mercamine
24. Mercaptamine
25. Mercaptoethylamine
26. Tartrate, Cysteamine
27. Tosylate, Cysteamine
1. 27761-19-9
2. Cysteamine (bitartrate)
3. Mercamine Bitartrate
4. Chebi:50386
5. Rp-103
6. Schembl49513
7. Chembl2062263
8. Bcp15048
9. Akos024332936
10. 2-aminoethanethiol 2,3-dihydroxysuccinate
11. Db-114321
12. Ft-0696891
13. 2-aminoethanethiol;2,3-dihydroxybutanedioic Acid
14. A900934
15. Q27122045
1. Cysteamine (usan)
2. Mecramine
Molecular Weight | 227.24 g/mol |
---|---|
Molecular Formula | C6H13NO6S |
Hydrogen Bond Donor Count | 6 |
Hydrogen Bond Acceptor Count | 8 |
Rotatable Bond Count | 4 |
Exact Mass | 227.04635831 g/mol |
Monoisotopic Mass | 227.04635831 g/mol |
Topological Polar Surface Area | 142 Ų |
Heavy Atom Count | 14 |
Formal Charge | 0 |
Complexity | 144 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 0 |
Undefined Atom Stereocenter Count | 2 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 2 |
Cystine Depleting Agents
Compounds and drugs that react with CYSTINE and convert it into a compound that can be more easily metabolized or intracellularly transported. Drugs in this class have been used to treat CYSTINOSIS. (See all compounds classified as Cystine Depleting Agents.)
Biophore is a research-driven global pharmaceutical company focused on niche APIs for the generic industry.
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 37094
Submission : 2022-06-01
Status : Active
Type : II
Transo-Pharm GmbH works globally to supply Active Pharmaceutical Ingredients adhering to the highest quality & GMP standards.
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 9619
Submission : 1992-09-30
Status : Active
Type : II
Registration Number : 225MF10146
Registrant's Address : Via Curiel 34, 20067 Paulo, Milano, ITALY
Initial Date of Registration : 2013-07-25
Latest Date of Registration : --
NDC Package Code : 12828-0068
Start Marketing Date : 1993-02-22
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 27574
Submission : 2013-07-25
Status : Active
Type : II
NDC Package Code : 12828-0068
Start Marketing Date : 1993-02-22
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
GDUFA
DMF Review : Reviewed
Rev. Date : 2015-05-26
Pay. Date : 2013-09-06
DMF Number : 26816
Submission : 2013-09-05
Status : Active
Type : II
GDUFA
DMF Review : Reviewed
Rev. Date : 2019-09-23
Pay. Date : 2019-09-12
DMF Number : 32668
Submission : 2018-04-13
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 38209
Submission : 2023-04-17
Status : Active
Type : II
Registration Number : 305MF10033
Registrant's Address : VIA M. Civitali, 1-20148 MILANO, ITALY
Initial Date of Registration : 2023-03-15
Latest Date of Registration : --
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 35758
Submission : 2021-03-29
Status : Active
Type : II
USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others
USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 7405
Submission : 1988-03-26
Status : Inactive
Type : II
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Biophore is a research-driven global pharmaceutical company focused on niche APIs for the generic industry.
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 37094
Submission : 2022-06-01
Status : Active
Type : II
GDUFA
DMF Review : Complete
Rev. Date : 2015-05-26
Pay. Date : 2013-09-06
DMF Number : 26816
Submission : 2013-09-05
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 27574
Submission : 2013-07-25
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 9619
Submission : 1992-09-30
Status : Active
Type : II
GDUFA
DMF Review : Complete
Rev. Date : 2019-09-23
Pay. Date : 2019-09-12
DMF Number : 32668
Submission : 2018-04-13
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 35758
Submission : 2021-03-29
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 38209
Submission : 2023-04-17
Status : Active
Type : II
USDMF
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 7405
Submission : 1988-03-26
Status : Inactive
Type : II
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
API Imports and Exports
Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
---|
Upgrade, download data, analyse, strategize, subscribe with us
DRUG PRODUCT COMPOSITIONS
Related Excipient Companies
Excipients by Applications
Global Sales Information
Market Place
Patents & EXCLUSIVITIES
ABOUT THIS PAGE
A Cysteamine Bitartrate manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Cysteamine Bitartrate, including repackagers and relabelers. The FDA regulates Cysteamine Bitartrate manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Cysteamine Bitartrate API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Cysteamine Bitartrate manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Cysteamine Bitartrate supplier is an individual or a company that provides Cysteamine Bitartrate active pharmaceutical ingredient (API) or Cysteamine Bitartrate finished formulations upon request. The Cysteamine Bitartrate suppliers may include Cysteamine Bitartrate API manufacturers, exporters, distributors and traders.
click here to find a list of Cysteamine Bitartrate suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Cysteamine Bitartrate DMF (Drug Master File) is a document detailing the whole manufacturing process of Cysteamine Bitartrate active pharmaceutical ingredient (API) in detail. Different forms of Cysteamine Bitartrate DMFs exist exist since differing nations have different regulations, such as Cysteamine Bitartrate USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Cysteamine Bitartrate DMF submitted to regulatory agencies in the US is known as a USDMF. Cysteamine Bitartrate USDMF includes data on Cysteamine Bitartrate's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Cysteamine Bitartrate USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Cysteamine Bitartrate suppliers with USDMF on PharmaCompass.
The Pharmaceuticals and Medical Devices Agency (PMDA) established the Japan Drug Master File (JDMF), also known as the Master File (MF), to permit Japanese and foreign manufacturers of drug substances, intermediates, excipients, raw materials, and packaging materials (‘Products’) to voluntarily register confidential information about the production and management of their products in Japan.
The Cysteamine Bitartrate Drug Master File in Japan (Cysteamine Bitartrate JDMF) empowers Cysteamine Bitartrate API manufacturers to present comprehensive information (e.g., production methods, data, etc.) to the review authority, i.e., PMDA (Pharmaceuticals & Medical Devices Agency).
PMDA reviews the Cysteamine Bitartrate JDMF during the approval evaluation for pharmaceutical products. At the time of Cysteamine Bitartrate JDMF registration, PMDA checks if the format is accurate, if the necessary items have been included (application), and if data has been attached.
click here to find a list of Cysteamine Bitartrate suppliers with JDMF on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Cysteamine Bitartrate as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Cysteamine Bitartrate API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Cysteamine Bitartrate as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Cysteamine Bitartrate and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Cysteamine Bitartrate NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Cysteamine Bitartrate suppliers with NDC on PharmaCompass.
Cysteamine Bitartrate Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Cysteamine Bitartrate GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Cysteamine Bitartrate GMP manufacturer or Cysteamine Bitartrate GMP API supplier for your needs.
A Cysteamine Bitartrate CoA (Certificate of Analysis) is a formal document that attests to Cysteamine Bitartrate's compliance with Cysteamine Bitartrate specifications and serves as a tool for batch-level quality control.
Cysteamine Bitartrate CoA mostly includes findings from lab analyses of a specific batch. For each Cysteamine Bitartrate CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Cysteamine Bitartrate may be tested according to a variety of international standards, such as European Pharmacopoeia (Cysteamine Bitartrate EP), Cysteamine Bitartrate JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Cysteamine Bitartrate USP).
LOOKING FOR A SUPPLIER?